At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 190 enrolled
Drug / intervention
PT027 +1 morecombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ALTA - ALbuterol/Budesonide Treatment in Acute Airway Obstruction. A Randomized, Double-blind, 2-period, Cross-over Study Evaluating Efficacy and Safety of Repeated Doses of PT027 Compared to PT007 in Patients With Asthma and Acute Airway Obstruction Induced by Repeated Mannitol Challenges
In Brief
A Phase 3 clinical trial evaluating PT027 and PT007 for Asthma. Completed, enrolled 190 participants across 1 site.
Detailed Summary
A study evaluating efficacy and safety of repeated doses of PT027 compared to PT007 in patients with asthma and acute airway obstruction induced by repeated mannitol challenges
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedSep 2022
Enrollment StartSep 2022
Primary CompletionNov 2024
TodayJul 2026
First PostedSep 26, 2022
Enrollment StartSep 28, 2022
Primary CompletionNov 18, 2024
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 3.8 years ago
Interventions
PT027combination
When administered PT027, participants will receive 2 actuations of albuterol- budesonide per dose administered as oral inhalations.
PT007combination
When administered PT007, participants will receive 2 actuations of albuterol administered as oral inhalations.